Management of relapsing–remitting multiple sclerosis in Qatar: an expert consensus
Healthcare systems vary greatly between countries. International, evidence-based guidelines for the management of multiple sclerosis (MS) may need to be adapted for use in particular countries. Two years ago, the authors published a comprehensive consensus guideline for the management of MS in Qatar. Since that time, the availability of disease-modifying treatments for relapsing–remitting MS (RRMS), and our understanding of how to apply those treatments, has increased. The authors present an update to our guidance, focussing on the management of relapsing–remitting RRMS. In particular, the authors consider the optimal use of different DMTs in patients presenting with mild, medium or high disease activity.
Other Information
Published in: Current Medical Research and Opinion
License: http://creativecommons.org/licenses/by-nc-nd/4.0/
See article on publisher's website: https://dx.doi.org/10.1080/03007995.2019.1669378
Funding
Open Access funding provided by the Qatar National Library.
History
Language
- English
Publisher
Taylor & FrancisPublication Year
- 2019
License statement
This Item is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.Institution affiliated with
- Hamad Medical Corporation
- Neuroscience Institute - HMC